News|Donald Trump‘Party of parents’: Trump touts government guidance to increase IVF accessCritics highlight that the cost-cutting proposals fall short of President Trump’s campaign pledge to make IVF free.
On Thu, Oct 16, 2025, the administration announced a strategic collaboration with EMD Serono, a subsidiary of Merck, aimed at reducing costs for fertility treatments in the United States. This initiative is part of the TrumpRx project, which is a…
On Thu, Oct 16, 2025, the administration announced a strategic collaboration with EMD Serono, a subsidiary of Merck, aimed at reducing costs for fertility treatments in the United States. This initiative is part of the TrumpRx project, which is a direct-to-consumer platform scheduled for launch in 2026.
EMD Serono, recognized as a leading manufacturer of fertility drugs, has committed to offering significant discounts on its products, including Gonal-F, widely used in in vitro fertilization (IVF). The agreement seeks to make fertility treatments more financially accessible to a broader segment of the population.
EMD Serono is the third major pharmaceutical company to join TrumpRx, following prior agreements with Pfizer and AstraZeneca. The initiative aims to provide reduced pricing on prescription drugs while encouraging manufacturing within the United States. Although initial tariff threats were a factor in securing these deals, the tariffs were postponed after successful negotiations.
The administration also introduced guidance to expand insurance coverage for IVF treatments. This includes provisions for supplemental insurance plans specifically for fertility, similar to existing options for vision and dental coverage. However, the effectiveness of these measures may be limited by the number of uninsured individuals and the availability of supplemental policies.
This initiative is part of the TrumpRx project, which is a direct-to-consumer platform scheduled for launch in 2026.
A recent court decision in Alabama, which classified IVF embryos as children, raised concerns about the future of IVF services. Legislative actions were taken to protect IVF providers from potential legal repercussions. The administration has emphasized its commitment to safeguarding access to reproductive healthcare.
These measures are positioned as part of a broader strategy to address demographic trends, including efforts to increase the national birthrate. The administration has highlighted the importance of reversing declining fertility rates and considers this a matter of national security.
The administration continues to advocate for employer-driven benefits solutions, allowing companies to tailor health plans to address infertility and related health issues. Discussions with insurance companies and employers are ongoing to facilitate the implementation of these new guidelines.
Based on reporting by Al Jazeera.
